|
|
name  click to compare prices |
| Allegra, Aprovel, Astra-Synthélabo | | Bio-Organics | | Cenovis, Chinoin Rt, Copaxone | | Eloxatine | | Irex | | Laboratorios Kendrick, Lactacyd, Lantus, Lipofactor, Lovenox | | Mitosyl | | Nature's Own | | Plavix | Sanofi-Aventis , Sanofi-Synthelabo , Stilnox | | Taxotere, Tritace |
» Shop local, ethical and at the best price on Ethishop  |
|
| |
|
| shareholder | country | % | source |
|
year | business source |
| 2007 | Sanofi-Aventis SA, France's largest drugmaker | |
| 2007 | Sanofi-Aventis is France's largest drugmaker. | |
| 2006 | Sanofi-Aventis is the world's fourth-largest pharmaceutical group. | Les Echos |
| 2006 | Sanofi-Aventis sells 23% of the vaccines bought in the world. | Les Echos |
| 2004 | The world's third-largest pharmaceutical company with 70 plants in the world, 19 of which in France. | |
|
country | address & contact : production type incentive source |
France | Montpellier : R&D Les Echos |
France | Toulouse : R&D Les Echos |
France | Chilly-Mazarin : R&D Les Echos |
France | Bagneux : R&D Les Echos |
France | Porcheville : R&D Les Echos |
Mexico | Laboratorios Kendrick : Production, médicaments génériques Les Echos |
|
year name | photo position; compensation source |
| 2002Dehecq, Jean-François |  Chief Executive Officer; salary: 1.9 million Eu€; stock-options: 6 million Eu€; Les Echos |
|
year | employees <> | social impact : country source |
| 2008 | -700 | Internal restructuring: Sanofi-Aventis removes a third of its medical representatives jobs in France.: France | Reuters |
| 2008 | 100000 -380 | Internal restructuring: Sanofi-Aventis cuts 380 jobs of medical representatives in Germany.: Germany | L'Expansion |
| 2007 | -40 | Internal restructuring: CanadaLes Echos | |
| 2007 | -118 | Internal restructuring: Sanofi-Aventis restructures its Neuville-on-Saone factory because of the fall of the sales of the Ketek drug.: France | Les Echos |
| 2005 | -504 | Merger/Acquisition: Following the merger between Sanofi and Aventis, 500 workers have accepted an early retirement program. They will earn 70% of their former wage.: France | Les Echos |
| 2004 | -330 | Internal restructuring: | La Vie Financière |
|
year | employees <> | social impact : country source |
|
year | country : consequences source |
| 2006 | France : The International Chamber of Commerce of Paris confirmed the "environmental responsibility" of Sanofi for the underground pollution with mercury of the Vieux-Thann site. | Les Echos |
|
year | country : consequences source |
|
year | financial misdemeanor | sales | income | | buyback | source |
| 2008 |
| | | | 1.227 | billion Eu€ | Les Echos |
| 2007 |
| | | | 1.787 | billion Eu€ | Les Echos |
| 2007 |
| 28.05 | 6.96 | |   | billion Eu€ | |
| 2007 |
Sanofi pays US$190 million to the US Department of Justice to settle allegations of fraud in the pricing and marketing of a drug used for cancer treatment side effects. From September 1997 to June 2004, Sanofi's subsidiary Aventis allegedly artificially inflate the price of the drug Anzemet, increasing the cost of government reimbursements for the drug. |
| | | |   | | AP |
| 2006 |
| 27.75 | 6.57 | |   | billion Eu€ | |
| 2004 |
| | | | 1.53 | billion Eu€ | Boursier.com |
| 2004 |
| 25 | | |   | billion US$ | |
| 2003 |
| 8.72 | 1.1 | |   | billion Eu€ | |
| 2003 |
| | | | 0.14 | billion Eu€ | Boursier.com |
| 2002 |
| 7.45 | 1.58 | |   | billion Eu€ | |
| 2001 |
| 6.49 | 0.98 | |   | billion Eu€ | |
| 2000 |
| 5.96 | 0.62 | |   | billion Eu€ | |
| 1999 |
| 5.35 | | |   | billion Eu€ | |
|
year | financial misdemeanor | sales | income | assets | buyback | source |
|
year | purpose : intermediary/lobby : institution source |
|
year | dubious practice : image source |
| 2005 | Arguable partnership: S'est allié à la fondation Drugs for Neglected Diseases Initiative pour la mise au point et la distribution d'ici 2006 d'un traitement à prix coûtant contre le paludisme. Le paludisme est une maladie délaissée par les centres de recherche des grands laboratoires privés. « On n'arrive pas à trouver une rentabilité, qui est à la base de nos projets de recherche, tout le monde le comprendra », explique Philippe Baetz, vice-président de Sanofi-Aventis.: value: Health; | Libération |
| 2004 | slogan: Nous refusons l'idée de ne pas développer les médicaments de demain pour un simple problème de taille; | |
| 1999 | slogan: L'essentiel, c'est la santé; | |
|
|
|